Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD and Food Effect Study of TBI-223 in Healthy Adults
NCT03758612Phase 1Completed
- Sponsor
- TB Alliance
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TBI-223 in Tuberculosis (TB) (12 arms), sponsored by TB Alliance. Primary endpoint: Number of Participants With Treatment-related Adverse Events. Started Jan 2019; status: completed.
02
Drugs
TBI-223
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03758612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758612.